For instance, in hormone-resistant breast cancer, mutations in estrogen receptor 1 gene (ESR1) are associated with acquired endocrine resistance14, and two ESR1 ligand-binding site mutations produced partial resistance to the currently available endocrine therapies15. This evidence concerns the gene ESR1 and breast carcinoma.